Low-intensity extracorporeal shockwave therapy (Li-ESWT) has attracted growing clinical and commercial interest as a noninvasive drug-free choice for erectile dysfunction (ED). Despite a mounting body of trial data, major international guidelines continue to classify it as investigational, raising important questions for clinicians about when and whether this technology belongs in routine practice.

Li-ESWT is among the most extensively studied noninvasive treatments for ED. This technology has been used in medicine for decades, including the fragmentation of kidney stones in urology and promotion of tissue repair in traumatology, although higher-intensity waves are used in those contexts.

Its application in sexual medicine emerged from the hypothesis that low-intensity acoustic pulses applied to different areas of penile tissue could induce biological changes in the vascular tissue, thereby improving the blood circulation required for an erection. The treatment does not require anesthesia and is typically delivered in cycles of six to 12 sessions, although protocols vary across clinical studies and medical centers.

ED Management

ED remains one of the most common male sexual disorders and is defined as the persistent inability to achieve or maintain an erection sufficient for satisfactory sexual intercourse. The prevalence increases with age, although younger men may also be affected, particularly in the presence of cardiovascular, metabolic, or psychological risk factors.

In Spain, approximately 1 in 5 men older than 18 years have some degree of ED. Despite this high prevalence, many individuals do not seek medical care, contributing to a substantial underdiagnosis.

Management follows a stepwise approach based on interventions with established clinical efficacy. First-line therapy includes phosphodiesterase type 5 (PDE5) inhibitors, such as sildenafil or tadalafil, which facilitate erection by enhancing vasodilation of cavernous tissue in response to sexual stimulation.

These medications demonstrate high efficacy in most patients with mild-to-moderate ED. When ineffective or contraindicated, intracavernosal injections of vasoactive agents may be used, directly inducing erection through smooth muscle action in the penile tissue.

When both strategies fail, penile prosthesis implantation remains the most effective option, permanently restoring erectile function (EF). Approximately 15% of patients do not respond to pharmacological therapy or injections and may be candidates for surgery.

Evidence Review

Alongside these options, regenerative therapies, such as Li-ESWT, have appeared, with promising findings in preliminary studies. However, most clinical guidelines classify these approaches as investigational or adjunctive, pending stronger evidence.

In recent years, Li-ESWT has been evaluated in multiple randomized clinical trials (RCTs) and systematic reviews aimed at determining its efficacy, particularly in patients with vasculogenic ED.

A 2025 meta-analysis of 12 randomized controlled trials, including 882 men with vasculogenic erectile dysfunction, showed that the therapy significantly improved scores on the EF domain of the International Index of Erectile Function-Erectile Function (IIEF-EF) compared with placebo or sham treatment. In parallel, it increased the proportion of patients achieving an Erection Hardness Score ≥ 3, a score considered sufficient for penile rigidity.

Similar findings were reported in a systematic review published in the Journal of Personalized Medicine in 2024. The analysis concluded that patients treated with Li-ESWT experienced statistically significant improvements in EF scales compared with placebo. In some trials, increases reached up to 5 points in IIEF-EF scores, which is considered clinically meaningful in patients with mild-to-moderate ED.

A 2025 evidence assessment also indicated that, compared with placebo or no treatment, this therapy increased both the mean IIEF-EF score and the proportion of patients achieving the minimal clinically significant difference.

However, researchers have noted important methodological limitations. Protocols vary widely, including differences in the number of sessions, energy levels applied, generator type, and treatment areas. Most studies have focused on mild-to-moderate vasculogenic ED, while evidence remains limited in patients with severe disease, advanced diabetes, or those who have undergone radical prostatectomy. The durability of the effect beyond 12 months also remains unclear because long-term follow-up data are limited.

Guideline Position

Despite encouraging findings, major international clinical guidelines maintain a cautious stance regarding shockwave therapy for ED. The American Urological Association classifies this intervention as investigational and recommends restricting its use to clinical trials or research protocols until stronger evidence on its efficacy and long-term safety becomes available. In the US, therapy does not have specific approval from the FDA for ED and is not covered by most insurance systems.

Similarly, a 2026 review in Sexual Medicine Reviews highlighted the absence of consensus on minimum treatment standards, including the number of sessions, energy flux density or pressure, pulse number, and cycle duration. These analyses call for larger multicenter RCTs with clearly defined and comparable protocols. They also emphasized the need to better define which patients are most likely to benefit and under what conditions before integration into routine clinical practice.

Despite these recommendations, the rapid commercial expansion of this technology in private clinics has raised concerns. In many cases, it is presented as an established therapy, despite the absence of a definitive scientific consensus. Reports have also highlighted substantial variability in devices, treatment protocols, and costs across centers.

Regenerative Options

Interest in shockwave therapy reflects a broader trend in ED research toward regenerative approaches that aim to reverse the underlying structural, vascular, and neural damage of the cavernous tissue, moving beyond transient facilitation of erection.

Platelet-rich plasma (PRP) is one such treatment strategy. This technique concentrates and reinjects autologous platelets to release growth factors that promote angiogenesis and tissue repair. Some centers are exploring intracavernosal PRP injections, which are sometimes combined with shockwave therapy to enhance the effects. Evidence remains limited to clinical series and preliminary studies, with a few RCTs.

Another area of investigation involves stem cell therapy; particularly mesenchymal cells derived from adipose tissue or bone marrow. Preclinical studies have shown improvements in penile blood flow and cavernous tissue regeneration with partial restoration of EF after vascular or nerve injury. The first human trials with small groups of patients have also reported sustained improvements over several months, although researchers emphasized that these are preliminary findings with limited follow-up.

Other experimental approaches include gene therapies targeting vascular signaling and combinations of regenerative treatments with conventional drugs. Some reviews suggest that therapies such as shockwaves may improve the response to PDE5 inhibitors in patients who previously did not respond to treatment, although this effect requires confirmation in controlled studies.

Currently, most of these therapies remain experimental. The potential of technologies such as Li-ESWT is notable, but a substantial gap persists between expectations and evidence. However, bridging this gap requires more homogeneous, large-scale, and long-term research.

This article was translated from El Médico Interactivo, part of the Medscape Professional Network.